Perioperative Lidocaine Infusions for the Management of Pain From Burn Injury
Launched by UNIVERSITY OF WASHINGTON · Feb 10, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether IV lidocaine, a medication given through an intravenous (IV) line, can help manage pain for patients with burn injuries who are undergoing a specific surgical procedure called wound debridement. The researchers hope that using lidocaine will reduce the need for stronger pain medications called opioids, improve overall pain control, and lower the chances of complications that can arise from using opioids for a long time.
To participate in this study, individuals must be at least 18 years old with acute burn injuries affecting less than 20% of their body. Participants will be randomly assigned to receive either the lidocaine treatment or a saline solution (placebo) during their surgery, and this treatment will continue for 48 hours afterward. They will be asked about their pain levels at different times during this period and again two weeks after surgery. Importantly, neither the participants nor the medical staff will know which treatment they are receiving to ensure fair results. This trial is not yet recruiting participants, but it aims to find new ways to manage pain effectively and safely.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute burn patients
- • 18 years or older
- • \<20% Total Body Surface Area
- • Wound debridement surgery scheduled at Harborview Medical Center
- Exclusion Criteria:
- • History of polysubstance use
- • Chronic opioid use (MED\>40mg for more than 6 weeks)
- • Cases where the known clinical standard care would be to keep patient intubated postoperatively
- • Cases where the known clinical standard care would avoid IV Lidocaine infusion
- • Allergy to amide local anesthetics
- • Any elevated risk for local anesthetic systemic toxicity as determined by the study team
- • Cardiac arrythmias or cardiovascular instability (e.g. shock)
- • Severe renal or hepatic impairment
- • Pregnancy
- • Local anesthesia will be given by another route (e.g. nerve block)
- • Prisoners
- • Non-English Speaking/reading
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ireana C Ng, MD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported